Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change
BioSpace
Sanofi's interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent's patents had anything to do with the departure of CEO Paul Hudson.
pharminent
April 23, 2026 (Last updated: April 23, 2026)
BioSpace
Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s patents had anything to do with the departure of CEO Paul Hudson.
